Company / R&D Expense
RAPT Therapeutics, Inc. R&D Expense History
FY2018-FY2024 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest R&D Expense
$107.2M
FY2024
5-year range
$45.5M / $107.2M
FY2020-FY2024
Trend
+6.2%
vs FY2023
Sector context
#133 of 208
Health Care
What the data says
At $107M, RAPT Therapeutics, Inc.'s r&d expense ranks #133 of 208 in the Health Care sector. R&D Expense has increased for 6 consecutive years, from $32M in FY2018 to $107M in FY2024.
Based on SEC 10-K filings.
$107M in FY2024 with a 5-year CAGR of +25.2%.
Improved from $67M to $107M over the past 2 years.
Health Care sector context is included.
R&D Expense over time
Growth rates
- 3-Year CAGR
- +23.5%
- 5-Year CAGR
- +25.2%
- 10-Year CAGR
- -
Sector benchmark
#133 of 208 in Health CareTop 64% of 208This company $107.2M Sector average $644.3M
▼
-83.4% below sector average
Key checks
Key Insights
- RAPT Therapeutics, Inc.'s r&d expense has grown for 6 consecutive years.
- 5-year CAGR of +25.2%, indicating consistent growth.
- In FY2024, r&d expense increased 6.2% year-over-year.
- Ranks #133 out of 208 companies in the Health Care sector.
Company context
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score 0.38 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | R&D ExpenseValue | YoY GrowthYoY |
|---|---|---|
| FY2024 | $107.2M | +6.2% |
| FY2023 | $101.0M | +50.6% |
| FY2022 | $67.1M | +17.7% |
| FY2021 | $57.0M | +25.3% |
| FY2020 | $45.5M | +30.3% |
| FY2019 | $34.9M | +9.9% |
| FY2018 | $31.8M | - |
As of FY2024 · SEC 10-K · Updated Feb 28, 2026